TY - JOUR
T1 - Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications
AU - Gerhart, Jacqueline L.
AU - Kalaaji, Amer N.
PY - 2010/6
Y1 - 2010/6
N2 - Background: Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking. Objective: We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease. Methods: We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality. Results: Of 334 patients identified, 7 (2.1%) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43%) died within 1 month of diagnosis, and none received PCP prophylaxis. Limitations: Retrospective study design and limited patient group are limitations. Conclusions: PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.
AB - Background: Pneumocystis carinii pneumonia (PCP) causes morbidity and mortality in immunocompromised hosts. Data describing use of PCP prophylaxis in immunosuppressed dermatologic patients are lacking. Objective: We sought to describe the frequency of PCP among dermatologic patients receiving immunosuppression for immunobullous disease or connective tissue disease. Methods: We retrospectively reviewed the cases of patients with immunobullous and connective tissue disease at our department of dermatology between 1980 and 2006 who received immunosuppression and had subsequent development of pneumonia. We recorded patient characteristics, use of PCP prophylaxis, whether PCP developed, and if so, their morbidity and mortality. Results: Of 334 patients identified, 7 (2.1%) were given the diagnosis of PCP during immunosuppressive treatment. Of these 7 patients, 3 (43%) died within 1 month of diagnosis, and none received PCP prophylaxis. Limitations: Retrospective study design and limited patient group are limitations. Conclusions: PCP prophylaxis may improve outcomes for some patients with immunobullous or connective tissue disease receiving immunosuppressive therapy.
KW - Pneumocystis carinii
KW - connective tissue disease
KW - immunobullous disease
KW - immunosuppression
KW - pneumonia
UR - http://www.scopus.com/inward/record.url?scp=77951938014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951938014&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2009.07.042
DO - 10.1016/j.jaad.2009.07.042
M3 - Article
C2 - 19828210
AN - SCOPUS:77951938014
SN - 0190-9622
VL - 62
SP - 957
EP - 961
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 6
ER -